Evidence map›Paper›PMID 39578853›Full record

ArticleAlzheimer's research & therapy2024

Elevated plasma p-tau231 is associated with reduced generalization and medial temporal lobe dynamic network flexibility among healthy older African Americans.

Miray Budak, Bernadette A Fausto, Zuzanna Osiecka, Mustafa Sheikh, Robert Perna, Nicholas Ashton, Kaj Blennow, Henrik Zetterberg, Patricia Fitzgerald-Bocarsly, Mark A Gluck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Elevation in network dynamics amplifies amyloid-dependent tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Miray BudakCenter for Molecular & Behavioral Neuroscience, Rutgers University-Newark, 197 University Avenue, Suite 209, Newark, NJ, 07102, USA. miray.budak@rutgers.edu.
Bernadette A FaustoCenter for Molecular & Behavioral Neuroscience, Rutgers University-Newark, 197 University Avenue, Suite 209, Newark, NJ, 07102, USA.
Zuzanna OsieckaCenter for Molecular & Behavioral Neuroscience, Rutgers University-Newark, 197 University Avenue, Suite 209, Newark, NJ, 07102, USA.
Mustafa SheikhCenter for Molecular & Behavioral Neuroscience, Rutgers University-Newark, 197 University Avenue, Suite 209, Newark, NJ, 07102, USA.
Robert PernaCenter for Molecular & Behavioral Neuroscience, Rutgers University-Newark, 197 University Avenue, Suite 209, Newark, NJ, 07102, USA.
Nicholas AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Wallinsgatan 6, Mölndal, Gothenburg, 431 41, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Wallinsgatan 6, Mölndal, Gothenburg, 431 41, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Wallinsgatan 6, Mölndal, Gothenburg, 431 41, Sweden.
Patricia Fitzgerald-BocarslyDepartment of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, Rutgers Biomedical and Health Sciences, Medical Science Building 185 South Orange Avenue, Newark, NJ, USA.
Mark A GluckCenter for Molecular & Behavioral Neuroscience, Rutgers University-Newark, 197 University Avenue, Suite 209, Newark, NJ, 07102, USA.

Funding

Risk Factors for Future Cognitive Decline and Alzheimer’s Disease in Older African Americans SUPPLEMENTR01AG053961 · NIA · RUTGERS THE STATE UNIV OF NJ NEWARK · PI MARK A GLUCK · 2018 to 2026
$10.6M
National Institutes of Health (NIH) and the National Institutes of Aging (NIA) 1R01AG053961NIA NIH HHS R01 AG053961Swedish Research Council #2022-01018 and #2019-02397
6 · The paper itself

Abstract

backgroundPhosphorylated tau (p-tau) and amyloid beta (Aβ) in human plasma may provide an affordable and minimally invasive method to evaluate Alzheimer's disease (AD) pathophysiology. The medial temporal lobe (MTL) is susceptible to changes in structural integrity that are indicative of the disease progression. Among healthy adults, higher dynamic network flexibility within the MTL was shown to mediate better generalization of prior learning, a measure which has been demonstrated to predict cognitive decline and neural changes in preclinical AD longitudinally. Recent developments in cognitive, neural, and blood-based biomarkers of AD risk that may correspond with MTL changes. However, there is no comprehensive study on how these generalization biomarkers, long-term memory, MTL dynamic network flexibility, and plasma biomarkers are interrelated. This study investigated (1) the relationship between long-term memory, generalization performance, and MTL dynamic network flexibility and (2) how plasma p-tau231, p-tau181, and Aβ42/Aβ40 influence generalization, long-term memory, and MTL dynamics in cognitively unimpaired older African Americans.

methods148 participants (Mean

resultsThere was a significant positive correlation between generalization performance and MTL Dynamic Network Flexibility (t = 3.372, β = 0.280, p < 0.001). There were significant negative correlations between generalization performance and plasma p-tau231 (t = -3.324, β = -0.265, p = 0.001) and p-tau181 (t = -2.408, β = -0.192, p = 0.017). A significant negative correlation was found between plasma p-tau231 and MTL Dynamic Network Flexibility (t = -2.825, β = -0.232, p = 0.005).

conclusionsIncreased levels of p-tau231 are associated with impaired generalization abilities and reduced dynamic network flexibility within the MTL. Plasma p-tau231 may serve as a potential biomarker for assessing cognitive decline and neural changes in cognitively unimpaired older African Americans.

Indexed as

Amyloid beta-PeptidesBiomarkersBlack or African Americantau ProteinsTemporal LobeAgedFemaleGeneralization, PsychologicalHumansMagnetic Resonance ImagingMaleMiddle AgedPeptide FragmentsPhosphorylationAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersMAPT protein, humanPeptide Fragmentstau ProteinsAfrican AmericansAmyloid-betaDynamic flexibilityGeneralizationMedial temporal lobePlasma p-tau

Identifiers

PMID39578853
PMCPMC11583385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.